– July 1, 2009
July 1, 2009
View Issues
-
Red Cells and Cancer I: ABO Blood Type and Risk for Pancreatic Cancer
In an evaluation of two large cohort studies (the Nurses' Health Study and the Health Professionals Follow-up Study), there was a slightly increased risk of pancreatic cancer in those with blood groups A, B, and AB relative to those with blood group O, such that approximately 17% of pancreatic cancer cases were attributable to the non-O blood group. -
Red Cells and Cancer II: Blood Donation and Cancer Risk
Evidence is presented from a case-control, retrospective analysis indicating a small but significant increased risk of cancer, particularly hematologic malignancy, among blood donors with a positive direct antiglobulin test (DAT). -
CA 19-9 and the Management of Pancreatic Cancer
In a retrospective analysis of a single institution's experience with CA 19-9 as a marker in patients with pancreatic cancer, the absolute level prior to therapy, and the drop after treatment, was shown to be an independent prognostic factor for survival. -
Long-term Outcomes for Anti-Helicobacter Treatment of Localized Gastric MALT Lymphoma
In a retrospective review of 105 patients treated exclusively with anti-Helicobacter therapy for locally confined gastric MALT lymphoma initial complete responses were achieved in 75% of cases and at a median follow-up of 6.3 years, disease relapse had occurred in only 13. -
Cord-Blood Transplantation Using Non-myeloablative Regimens
Plerixafor is a novel inhibitor of stromal cell-derived factor (SDF-1) that promotes efficient hematopoietic cell mobilization. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch
Clopidogrel and proton pump inhibitors; adverse events with tamsulosin after cataract surgery; new guidelines for persistent pain in the elderly; and FDA Actions.